Search results for "Pharmacotherapy"

showing 10 items of 283 documents

Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan

2009

A range of angiotensin II receptor blockers (ARB) is available, and analyses suggest there are differences between agents in terms of antihypertensive efficacy and 24-hour blood pressure control.This review assesses the data comparing olmesartan with other ARBs in terms of blood pressure reductions, goal achievement, 24-hour control and speed of onset. Olmesartan seems to have a more favourable efficacy profile relative to standard doses of the ARBs used in comparative studies; results consistent with the high degree of blockade of the angiotensin II type 1 receptor for olmesartan.Taken together, there might be differences between ARBs regarding their blood pressure lowering efficacy, and …

Medicine (General)Angiotensin receptorReceptors AngiotensinAngiotensin Receptor Antagonistsbusiness.industryImidazolesTetrazolesBlood PressurePharmacologyAngiotensin IIBlockadeAngiotensin Receptor AntagonistsR5-920Treatment OutcomeEndocrinologyBlood pressurePharmacotherapyRenin–angiotensin systemInternal MedicineHumansMedicineDrug Therapy CombinationbusinessOlmesartanmedicine.drugJournal of the Renin-Angiotensin-Aldosterone System
researchProduct

Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic…

2010

Summary Introduction Post-neurosurgical nosocomial meningitis has become an important subgroup of bacterial meningitis in the hospital setting. The increase in meningitis caused by multidrug-resistant (MDR) Acinetobacter baumannii has resulted in a significant reduction in available treatment options. Case report and literature review We report the case of a 36-year-old man with a complex craniofacial trauma, who developed a nosocomial meningitis due to MDR A. baumannii that was cured by intrathecal colistin. The case is contextualized among all the published cases of Acinetobacter meningitis treated with topical colistin found through a MEDLINE search of the literature. To date, including …

Microbiology (medical)Acinetobacter baumanniiAdultMalemedicine.medical_specialtymedicine.drug_classIntraventricularAntibioticsNeurosurgeryIntrathecalMeningitis BacterialPharmacotherapyPostoperative ComplicationsInternal medicineDrug Resistance Multiple BacterialMedicineCraniocerebral TraumaHumansMeningitisInjections SpinalbiologyAcinetobacterbusiness.industryColistinAcinetobacter; Colistin; Intrathecal; Intraventricular; Meningitis; NeurosurgeryGeneral MedicineAcinetobacterbiochemical phenomena metabolism and nutritionbiology.organism_classificationmedicine.diseaseSurgeryAcinetobacter baumanniiAnti-Bacterial AgentsMultiple drug resistanceMeningitiInfectious DiseasesTreatment OutcomeColistinNeurosurgerybusinessMeningitismedicine.drugAcinetobacter Infections
researchProduct

Toxoplasmosis after hematopoietic stem cell transplantation.

2000

In immunocompromised individuals, toxoplasmosis mostly occurs as a reactivation of a latent infection, causing severe to life-threatening disease. Thus, recipients who are seropositive for Toxoplasma gondii before an allogeneic hematopoietic stem cell transplant (HCT) are at highest risk, although primary infections may also cause severe toxoplasmosis. The disease most often affects the central nervous system, but in HCT recipients other organs are involved in more than half of the cases. Because of the alteration of the immune response in these patients, serodiagnosis is not sufficiently reliable in the diagnosis of post-HCT toxoplasmosis, and direct detection of the causative agent is req…

Microbiology (medical)AdultMaleAdolescentmedicine.medical_treatmentAntiprotozoal AgentsSulfadiazineHematopoietic stem cell transplantationDiseasePharmacotherapyImmunopathologyTrimethoprim Sulfamethoxazole Drug CombinationmedicineAnimalsHumansChildSurvival ratebiologybusiness.industryClindamycinHematopoietic Stem Cell TransplantationToxoplasma gondiiMiddle Agedmedicine.diseasebiology.organism_classificationToxoplasmosisTransplantationSurvival RateInfectious DiseasesPyrimethamineImmunologyDrug Therapy CombinationFemaleAutopsybusinessToxoplasmaToxoplasmosisClinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct

Toxoplasmosis, a severe complication in allogeneic hematopoietic stem cell transplantation: successful treatment strategies during a 5-year single-ce…

1999

Toxoplasmosis is a rare but often fatal complication that occurs after patients undergo allogeneic hematopoietic stem cell transplant. At our institution, toxoplasmosis was diagnosed in 8 of 301 patients who received stem cell transplants. Disseminated toxoplasmosis with a rapid fatal course was observed in 2 patients. Six patients had cerebral toxoplasmosis diagnosed on the basis of neurological signs and observation of the patients' mental confusion, seizures, and typical lesions (which were assessed by computed tomography, magnetic resonance imaging, or both). Seroconversion of antitoxoplasma immunoglobulin and a discovery of toxoplasma deoxyribonucleic acid in the cerebrospinal fluid (c…

Microbiology (medical)AdultMalePathologymedicine.medical_specialtyPediatricsmedicine.medical_treatmentAntibodies ProtozoanSulfadiazineHematopoietic stem cell transplantationSingle CenterPharmacotherapySulfadiazinemedicineAnimalsHumansTransplantation HomologousSeroconversionbusiness.industryClindamycinHematopoietic Stem Cell TransplantationMiddle Agedmedicine.diseaseMagnetic Resonance ImagingToxoplasmosisTransplantationInfectious DiseasesPyrimethamineImmunoglobulin MToxoplasmosis CerebralDrug Therapy CombinationFemalebusinessComplicationTomography X-Ray ComputedToxoplasmamedicine.drugClinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.

2014

Item does not contain fulltext Plasma triglyceride concentration is a biomarker for circulating triglyceride-rich lipoproteins and their metabolic remnants. Common mild-to-moderate hypertriglyceridaemia is typically multigenic, and results from the cumulative burden of common and rare variants in more than 30 genes, as quantified by genetic risk scores. Rare autosomal recessive monogenic hypertriglyceridaemia can result from large-effect mutations in six different genes. Hypertriglyceridaemia is exacerbated by non-genetic factors. On the basis of recent genetic data, we redefine the disorder into two states: severe (triglyceride concentration >10 mmol/L), which is more likely to have a mono…

Multifactorial InheritanceSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Genome-wide association studyDisease030204 cardiovascular system & hematologyISCHEMIC-HEART-DISEASEBioinformaticshypertriglyceridaemia0302 clinical medicineEndocrinologyGENERAL-POPULATIONHypertriglyceridemiatreatmentmedicine.diagnostic_testREMNANT CHOLESTEROLCombined Modality Therapy3. Good healthLIPASE DEFICIENCYdiagnosiPLASMA TRIGLYCERIDESDENSITY-LIPOPROTEIN CHOLESTEROLCARDIOVASCULAR-DISEASEPractice Guidelines as TopicBiomarker (medicine)Multifactorial Inheritancemedicine.medical_specialty030209 endocrinology & metabolismHealth PromotionArticle03 medical and health sciencesPharmacotherapyInternal medicineInternal MedicinemedicineAnimalsHumansHOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIAGenetic Predisposition to DiseaseAlleleGENOME-WIDE ASSOCIATIONLife Stylehypertriglyceridaemia; diagnosis; treatmentTriglyceridesGenetic testingbusiness.industryHypertriglyceridemianutritional and metabolic diseasesmedicine.diseaseEndocrinologyNONFASTING TRIGLYCERIDESbusinessBiomarkersThe lancet. Diabetesendocrinology
researchProduct

Response to initial treatment of multisystem langerhans cell histiocytosis: An important prognostic indicator

2002

Background Reliable prediction of prognosis allowing risk-adapted therapy remains a major issue in the management of multisystem Langerhans cell histiocytosis (LCH). In a recent publication of the International LCH Study Group, response to initial therapy appears to be a reliable outcome predictor. The aim of this study is to test this observation in a cohort of patients treated with more intensive initial therapy. Furthermore, we compare the predictive value of response to initial therapy to some other well-established stratification systems. Procedure Response to initial combination chemotherapy (prednisolone, vinblastine, and etoposide) at 6 weeks and its prognostic value was evaluated r…

OncologyCancer Researchmedicine.medical_specialtybusiness.industryRetrospective cohort studyCombination chemotherapymedicine.diseaseSurgeryHistiocytosisPharmacotherapyOncologyLangerhans cell histiocytosisInternal medicinePediatrics Perinatology and Child HealthCohortmedicinePrednisolonebusinessSurvival ratemedicine.drugMedical and Pediatric Oncology
researchProduct

How to optimize HCV therapy in genotype 1 patients: predictors of response.

2013

The advent of triple therapy (TT) with first-generation protease inhibitors boceprevir (BOC) and telaprevir (TVR) in addition to pegylated interferon and ribavirin (PEG-IFN/RBV) has resulted in a significant improvement in the sustained virological response (SVR) rate and potentially in life years gained compared to dual therapy (DT), when treating naive or treatment-experienced patients with genotype 1 (G1) chronic hepatitis C (CHC). This benefit is partly offset by the increased complexity of treatment, and the increased costs and risks of therapy, making it necessary to optimize the indications for TT. Naive patients with mild fibrosis and the IL28B CC polymorphism and/or with a rapid vi…

OncologyLiver Cirrhosismedicine.medical_specialtyGenotypeHepacivirusAntiviral AgentsTelaprevirchemistry.chemical_compoundPharmacotherapyPegylated interferonRisk FactorsInternal medicineBoceprevirmedicineHumansPrecision MedicineHepatologybusiness.industryRibavirinInterleukinsPatient SelectionHepatitis CHepatitis C ChronicViral Loadmedicine.diseaseTreatment OutcomechemistryPharmacogeneticsImmunologyHCVDrug Therapy CombinationInterferonsbusinessViral loadPharmacogeneticsmedicine.drugLiver international : official journal of the International Association for the Study of the Liver
researchProduct

GM-CSF in a Double-Blind Randomized Placebo-Controlled Trial in Therapy of Adult Patients with De Novo Acute Myeloid Leukemia

1994

Despite the fact that 60%–70% of patients with de novo acute myeloblastic leukemia (AML) achieve a complete remission (CR) of the disease only about 20%–30% of the patients remain in long term remission and are probably cured [1,2]. These rather disappointing long-term results argue in favor of an even more intensive induction and post-remission therapy. This intention is, however, at time limited by therapy associated toxicity. Especially haematotoxicity seems to be the limiting factor in that patients with profound neutropenia are at high risk of developing fatal infectious complications [3]. In this context haematopoietic growth factors, such as granulocyte-macrophage colony-stimulating …

Oncologymedicine.medical_specialtyAcute myeloblastic leukemiabusiness.industryPlacebo-controlled studyMyeloid leukemiaNeutropeniamedicine.diseaseGranulocyte colony-stimulating factorHaematopoiesisPharmacotherapyInternal medicineImmunologymedicineCytarabinebusinessmedicine.drug
researchProduct

Treatment sequence of synchronously (liver) metastasized colon cancer

2016

No standards for staging, systemic therapy or the timing of an operation are defined for patients newly diagnosed with synchronous metastases and a primary in the colon. An expert group of radiologists, medical, radiation and surgical oncologists therefore came together to discuss staging and treatment sequence for these patients and came up with a recommendation based on current evidence of potential therapeutic options. The discussion was organized to debate recommendations centred on 5 topics and therefore the position paper is built upon these titles and their subtitles. Editrice Gastroenterologica Italiana S.r.l.

Oncologymedicine.medical_specialtyColonColorectal cancermedicine.medical_treatment030230 surgeryTreatment sequenceSystemic therapy03 medical and health sciencesLiver metastases0302 clinical medicinePharmacotherapyDrug TherapyInternal medicinemedicineHepatectomyHumansCombined Modality TherapyTreatment optionsNeoplasm StagingHepatologybusiness.industryGeneral surgeryLiver NeoplasmsGastroenterologyAntineoplastic Protocolsmedicine.diseaseCombined Modality TherapyExpert groupColorectal cancerLiver030220 oncology & carcinogenesisPosition paperHepatectomyColorectal NeoplasmsbusinessSynchronous presentation
researchProduct

Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up.

2010

Oncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentColonoscopyPharmacotherapyMeta-Analysis as TopicRisk FactorsInternal medicineEpidemiologyAntineoplastic Combined Chemotherapy ProtocolsmedicineSecondary PreventionHumansSurvival analysisEarly Detection of CancerNeoplasm StagingRandomized Controlled Trials as TopicChemotherapymedicine.diagnostic_testbusiness.industryIncidenceCancerHematologyColonoscopymedicine.diseasePrognosisSurvival AnalysisSurgeryCarcinoembryonic AntigenEuropeTreatment OutcomeOncologyChemotherapy AdjuvantColonic NeoplasmsbusinessAdjuvantFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct